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Colorectal cancer (CRC) is the third leading cause of cancer-related death in the 
United States. During the tumorigenesis and metastasis of CRC, cells encounter 
numerous cellular and molecular events. ATF3, a member of the ATF/CREB 
transcription factor family, plays an important role on regulation of apoptosis and is 
regarded as a potential molecular target for chemoprevention and chemotherapy of 
colon cancer. The current study was performed to investigate cellular and molecular 
mechanisms by which ATF3 affects colon cancer-related phenotypes including 
apoptosis and metastasis. Here, we demonstrated that knockdown of ATF3 using 
small interfering RNA (siRNA) promotes the expression of anti-apoptotic protein, B-
cell lymphoma 2 (Bcl-2), in colon cancer cells, while overexpression of ATF3 
resulted in a dramatic decrease in Bcl-2 protein. Gain of function of ATF3 in colon 
cancer cell line HCT116 led to an increase of pro-apoptotic protein Bcl-2 homologous 
antagonist killer (Bak), followed by the induction of apoptosis. Furthermore, we 
observed that ATF3 overexpression downregulated expression of epithelial-
mesenchymal transition (EMT)-related transcription factors. However, mammosphere 
forming assay indicated that ATF3 overexpressed colon cancer cells form larger and 
more budding sites compared to control, which is associated with an increase of 
cluster of differentiation 44 (CD44) expression and a decrease of retinoblastoma (Rb) 
and tight junction protein zonula occludens (ZO)-1.  This study suggested that ATF3 
may play a dichotomous role in regulation of apoptosis and metastasis in colon 
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Chapter 1. Introduction 
1.1 Introduction 
 Cancer is a major cause of death in the world. The American Cancer Society 
estimates that 1,658,370 men and women will be diagnosed and 589,430 cancer deaths 
will occur in the United States in 2015 (1). Colorectal cancer (CRC) is the third leading 
cause of cancer mortality in the Western world (1). Cost-effective therapies and 
preventive approaches to treat colorectal cancer are urgently needed. Chemopreventive 
strategy using dietary compounds which prevents or delays the onset of several types of 
cancer, has gained a great deal of attention,  (2). Various bioactive phytochemicals, such 
as flavonoids (3-8), proanthocyanidins (9-11), carotenoids (12-16), isothiocyanates (17-
24), and sphingolipids (25-29) have been shown to exert anti-cancer activities in CRC 
(30). The mechanisms of their chemopreventive actions include targeting specific genes 
and modulating of oncogenic or tumor suppressive signaling pathways that lead to 
changes of cell proliferation, differentiation, survival, cell cycle progression, and 
metastasis (30).  
 During the course of tumorigenesis, cells encounter numerous cellular and 
physical stresses (31). Cells respond to stress in various ways ranging from promotion of 
cell survival to elicitation of the programmed cell death and removal of the damaged cells 
(32). However, the failure to restrain and eliminate stress signals can increase the risk of 
cancer (33-35). Activating transcription factor 3 (ATF3) is a member of the ATF/CREB 
family, which shares basic region-leucine zipper (bZip) DNA binding domain (36). 
Previous research has demonstrated that ATF3 is encoded by an immediate early gene (36) 
and its baseline mRNA level is low in normal cells. ATF3 can be induced by various 
stress stimuli and signals that damage the cells or tissues. These stress signals include 
hypoxia, anoxia, carcinogens, DNA damage, UV exposure and radiation (36, 37). 
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Comprehensive research found that ATF3 can participate in several cellular processes and 
adapt to different extra- and intra-cellular stimuli (36, 38).  
 In previous studies, we and other groups reported that ATF3 is a molecular target 
of many anti-cancer compounds and mediates the compound-stimulated apoptosis (39-42). 
However, several current studies demonstrated that ATF3 could either promote or 
suppress the cell proliferation and apoptosis in cancer cells (43). Besides, xenograft 
models showed ATF3 possessed either tumor suppressive or oncogenic activity (44-47). 
To better understand the role of ATF3 in colon cancer progression and increase the 
efficacy of anti-tumorigenic compounds targeting ATF3, in this project, we examined the 
changes of cellular gene expression and cell morphology after overexpression or 
knockdown of ATF3. 
 
1.2 Overview of cancer development and tumorigenesis 
1.2.1 Tumor cell apoptosis and Bcl-2 protein family 
 Apoptosis is a major mode of programmed cell death, which serves as an essential 
barrier for cancer development in multicellular organisms. By eliminating the damaged or 
aged cells, cell death balances the cell proliferation and contributes to the tissue 
homeostasis, development and immunity (48). The cellular cascade of molecular events 
involved in apoptosis is highly complex, and they can be categorized into two main 
pathways: the death receptor (extrinsic) pathway and the mitochondrial (intrinsic) 
pathway, with evidence indicating that the two pathways are interactive (49).  
 The function and activity of mitochondrial pathway mainly depends on the 
dynamic interaction between subgroups of Bcl-2 family proteins on the mitochondrial 
outer membrane. The Bcl-2 family proteins, which control the mitochondrial membrane 
permeability, can be further categorized into BH3-only proteins (delivering initiation 
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signals) (e.g. BIM PUMA, BAD, BIK), anti-apoptotic proteins (e.g. Bcl-2, Bcl-x, Bcl-XL, 
Bcl-w, BAG), and pro-apoptotic proteins (e.g. Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, and 
Blk) (31, 48). Accumulation of cytotoxic stresses suppresses the activity of anti-apoptosis 
proteins, whereas it triggers the pro-apoptotic proteins BAX and BAK to form the 
oligomers and increases the permeability of mitochondrial outer membrane. As a result, 
cytochrome c is released to cytosol where they bind to apoptotic protease activating factor 
1 (APAF1), recruits caspase 9 enzyme and activate caspase 3 (50). Aberrant expression of 
Bcl-2 family proteins is widely observed in various malignancies, and therapeutic 
strategy targeting Bcl-2 family proteins is promising. For example, anti-apoptotic protein 
Bcl-2 is frequently overexpressed in estrogen receptor-positive breast cancer, and the 
BH3 mimetic ABT-737 targeting Bcl-2 can improve tumor response to antiestrogen 
tamoxifen (51).   
 With better understanding of the signaling cascades, many approaches and assays 
are available for detecting and counting the apoptotic cells. The annexin V, a Ca+-
dependent phospholipid-binding protein, is widely used as a marker of apoptosis. During 
early apoptosis, annexin V can bind to phophatidylserine residues that translocate from 
inner surface of membrane to the outside of the cell due to the increased permeability (52).  
 
1.2.2  Tumor cell cycle 
 Cell cycle refers to the sequence of activities carried out by a cell leading to 
self-division and duplication. It proceeds through the activation of cyclins and cyclin-
dependent kinases (CDKs) to ensure successive transition from G1 to S and G2 phase 
and then the initiation of mitosis. Cyclin/CDK complexes are formed and switched on 
and off during different phases of the cell cycle progression through phosphorylation 
of target proteins (53). For example, the Cyclin D and CDK4/6 complex 
phosphorylates and inactivates its target protein, retinoblastoma and subsequently 
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cause G1/S transition and stimulate cell cycle (55). Whereas, cyclin A/E and CDK2/1 
complex regulates progression through S/G2/M phases (53, 54).  
 The activities of cyclin/CDK complexes are suppressed by CDK inhibitors, 
depending on the specificity between target CDK and inhibitor (56). The first class of 
inhibitors includes the INK4 proteins that bind to catalytic subunits of CDK4 and 
CDK6, but not other CDKs or D-type cyclins. The second family inhibitors of 
Cip/Kip proteins like p21 and p27 are more broadly acting, which inhibit all types of 
cyclin and CDK complexes at any phase without dissociating cyclin–CDK complexes 
(56, 57). 
 Structural studies show that p21 and p27 share similar primary structure and 
exert inhibition effect over the target proteins (58). At the beginning of the catalytic 
reaction, α-helix of Cip/Kip protein first makes contact with cyclin, followed by a 
deep insertion of second helix inside the catalytic cleft, and blocks the loading of ATP. 
Further conformational changes of CDK2 are observed to lock the catalytic cleft to an 
inactive form (57). Some studies have shown that highly expressed p27 can also 
inhibit CDK4 activity (59).  
 
 
1.2.3 Tumor cell metastasis: Single cell migration (EMT) vs. Collective invasion 
 Metastasis is a collective term which describes a process that a tumor cell leaves 
the primary tumor, travels to a distant site via the circulatory system, and establishes a 
secondary tumor. Metastasis is initiated by invasion. During the invasion, cancer cells 
may (or may not, depends on the migration model chosen) lose cell-cell or cell-matrix 
attachment which triggers matrix degradation followed by migration. Depending on the 
cell context and tissue environment, cells use two different models for migration: single 
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cell migration with the absence of cell-cell attachment, and collective cell migration along 
with the maintenance of the cell-cell junction. Cancer cell move into lumina blood and 
lymphatic vessels during intravasation and then circulates in the blood vessel. Many 
cancer cells will be trapped, however, those escape from the arrest can be transported to 
the new site (60). 
 Metastasis is responsible for 80% of death in cancer patients. Invasive tumor 
cells divide rapidly in an aggressive primary mass and variety of stromal cells in the 
surrounding microenvironment can be recruited to tumors. The hijacked tumor-
associated stroma cells can be educated and in turn, support tumor growth by 
producing growth factors and proteolytic enzymes (61). 
 Cells migration occurs in two major modes. Single cell migration, when cell-
cell adhesions are absent, and multicellular, collective cell migration, when cell-cell 
junctions are retained (60). The single cell migration is executed in a series of 
physicochemical steps within the same cell, which allows the cell body to protrude 
and generate traction force (60). 
  
Epithelial Mesenchymal Transition 
 Epithelial Mesenchymal Transition (EMT) is an essential embryonic process 
that causes the epithelial cells to lose their characteristics and switch to motile 
mesenchymal ones. This transition involves changes in cell morphology, size and 
behavior that is characterized by loss of cell junctions and apical-basal polarity, 
followed by the acquisition of a fibroblastic motility. These changes lead to a 
degradation of extracellular matrix and facilitate the cell migration and invasion (62-
64). EMT is initiated by the change in gene expression profile. The main EMT-
associated transcription factors include of the Snail, Slug, ZEB-1, SIP-1 and Twist 
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(64-68). Although a majority of EMT transcription factors are highly up-regulated at 
early EMT, each type shows distinct expression profiles depending on the cellular 
context, tissue type and progression stage of EMT. In addition, they control 
reciprocally and synergistically target a specific gene, thus leading to either repression 
of the epithelial genes or activation of mesenchymal genes (67, 68). 
 Activation of EMT transcription factors leads to a downregulation of E-
cadherin (epithelial maker) and an upregulation of N-cadherin (mesenchymal marker), 
thereby decreasing the cell adhesion. For example, SNAIL proteins, such as Snail and 
Slug, repress transcription of the E-cadherin by directly binding to E-box DNA 
sequences in the promoter region. This transcriptional suppression is associated with 
histone modifications of Polycomb repressive complex2 (PRC2), specifically 
methylation and acetylation at histone H3 Lys4 (H3K4), H3K9 and H3K27 (68). 
Additionally, SNAIL can also induce the mesenchymal phenotype by activating N-
cadherin. 
 Multiple signaling pathways have been implicated to regulate the initiation 
and progression of EMT by either activating or suppressing SNAIL expression. 
Glycogen synthasekinase-3β (GSK3β) directly phosphorylates Snail at two Ser-rich 
consensus motifs and inactivates its transcriptional activity (68). However, Wnt and 
PIK2-AKT pathway activate transcriptional activity of SNAIL by suppressing GSK3β 
activity (69-71). Activation of Wnt and EMT factors lead to an increase of stability of 
cytoplasmic β-catenin (68). Increased β-catenin translocate to nucleus where it forms 
β-catenin-TCF-4 complex and promotes the transcription of target gene (72).  
 Similarly, Twist expression is associated with the E-cadherin and N-cadherin 
gene expression along with SNAIL. Twist can be up-regulated by transcription factor 
hypoxia-inducible factor 1α (HIF1α) under hypoxia conditions, inducing angiogenesis 
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(73). Additionally, TWIST can also interact with methyltransferase SET8, thus 
mediates the H4K20 monomethylation, which is a histone mark linked to repression 
of E-cadherin and promotion of N-cadherin (74).  
 
Collective invasion 
 Over the decades, scientists have studied the possible mechanisms underlying 
single cell migration in both normal and malignant cells, involving the governing of 
cell adhesion and cytoskeleton dynamics (75-77). However, they failed in defining the 
rate-limiting mechanisms, such as dominant signaling pathway, receptor-ligand 
interaction, or protease-substrate interaction, which regulate invasive cancer cell 
migration. As an alternative, cancer invasion is now considered as a heterogeneous 
and adaptive process. The “plasticity” of invasion in cell adhesion, cytoskeletal 
dynamics, and mechanotransduction, together with other hallmarks of cancer, 
orchestrates morphological, signaling, and genetic alteration, and help the adaptation 
of cancer cells in even adverse tumor microenvironment (77-85).  
 Collective invasion requires cell-cell adhesion as well as coordination between 
various cells, which results in the co-existance of multicellular groups at the interface 
between tumor and stroma (85-87). Collective invasion exhibit different 
morphologies depending on the cell types, the number of jointly moving cells, and the 
tissue structure (85). For example, cells may form small clusters, solid strands or even 
an inner lumen, if epithelial polarity is retained. In some other ways, collective 
invasion can also present with a bud-like protruding site consisting of multiple cells 
with variable positions (60, 85).  
 
1.2.4 Tumor growth and cancer stem cell  
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 Carcinomas are cancers and malignancies that caused by multistep progression 
from benign low-grade adenomas. Researchers using different models have shown 
that unrestricted growth occurred in both benign and malignant tumors during 
complex tumor-progression process can be attributed to cancer stem cells (88). 
Physiologically, stem cells are undifferentiated cells that are capable of differentiating 
to all tissues during embryonic development, resulting in both self-renewal and 
differentiation to second daughter cell. Variety of signaling pathways are involved in 
the generation of stem cells (89, 90). Mutations in crucial pathways, such as Notch, 
Wnt and Hedgehog pathways, can cause normal stem cells to function abnormally, 
and accumulation of these genetic alterations can be responsible for malignancy (91). 
These malignant stem cells are considered as cancer stem cells (CSCs). 
 CSCs are considered as the driving forces for tumor growth malignancy, and 
the seeds for metastatic expansion of the tumor and cancer reoccurrence after surgery 
or chemotherapy (92). Certain characteristics were associated with CSC-enriched 
cancer cell populations in vitro (93): (i) CSCs in solid tumors can be identified using 
an extensive list of cell-surface markers (94-99). For example, colon cancer stem cell 
populations are rich in cell surface proteins CD133, CD24 and CD44 markers, which 
are usually associated with aggressive cancer types and poor prognosis (100). (ii) 
CSC-enriched cell populations are prone to form tumor mammospheres or 
tumorspheres (101), which are spherical colonies in suspension cultures. (iii) CSC-
enriched cell populations are hard to eliminate, which are associated with increased 
resistance to chemotherapeutic agents and radiotherapy (102-107).  
 CSCs protein marker CD44 is a transmembrane glycoprotein, together with its 
alternatively spliced variants, functions as receptors of hyaluronan and connects the 
actin cytoskeleton by the adaptor protein. CD44 expression is essential for 
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maintaining the cancer stem cell phenotype and promoting primary tumor growth of 
mammary cells (157). In particular, CD44 expression is essential for collective cell 
migration and subsequence metastatic progression initiated by loss of Rb function 
(138). Rb can suppress collective invasion, circulation and metastasis of cancer cells 
in CD44-dependent manner (138). 
 
1.3 The biological activities of ATF3 in cancer development 
1.3.1 Characteristics of ATF/CREB family of transcription factors 
 Activating transcription factor, or ATF, was first  identified in 1987 by Lee 
and his colleagues as a factor that can activate the transcription of the E1A-inducible 
adenovirus promoters E2A, E3, and E4 (109). In the same year, Montminy and 
Bilezikjian characterized a nuclear protein that can bind to the cAMP response 
element (CRE) in the somatostatin gene, and they named it CRE binding protein or 
CREB.  Later, ATF was found to be identical to the CREB, since ATF directly binds 
to the consensus sequence 5’-TGACGTCA-3’ and transactivates cAMP-inducible 
somatostatin gene (110). Since then, multiple factors that bind to this consensus 
sequence have been isolated (38). Those factors constitute ATF/CREB family with 
nearly 20 members and were classified into subgroups according to their amino acid 
similarity: the CREB/CREM, CRE-BP1 (commonly known as ATF2), ATF3, ATF4, 
ATF6 and B-ATF subgroups (38, 43). 
 All ATF/CREB proteins share similar basic region-leucine zipper (bZip) DNA 
binding domain, within each subgroups (38). ATF/CREB proteins form homodimers 
and selective heterodimers with other bZip proteins (for example, the AP-1 and 
C/EBP families of proteins) (36, 38). Despite their structural similarity, ATF/CREB 
proteins exhibit various different biological functions because different types of 
 10 
homo- or hetero-dimers determine DNA binding specificity and transcriptional 
activities of their genes (38). One common biological response of the ATF/CREB 
family is induction of a variety of stress signals in the cells (44).   
 The human ATF3 was first cloned by Dr. Hai and her colleagues in 1989 from 
cDNA library prepared of HeLa cells (111). The human ATF3 gene is localized in 
chromosome 1q32.3, and derived from four exons (as exons A, B, C, and E) with over 
15 kilobases (112). Exon A contains the 5’-untranslated region with a length of 167bp. 
Exon B incudes the AUG initiation codon and encodes first 80 amino acids of ATF3. 
Exon C encodes 36 amino acids that made up by basic region. Exon E encodes 65 
amino acids, which contains both the leucine zipper (ZIP) domain and the 3’-
untranslated region. Each exon B, C, and E each encodes a functional domain.  
 Like other ATF/CREB family members, ATF3, is a transcriptional factor and 
can both activate and repress the transcription of the target gene  through formation of 
either hetero- or homo- dimers. ATF3 homodimer auto-represses itself 
transcriptionally by recruiting inhibitory cofactors to its own promoter whereas ATF3 
heterodimer can either activate or repress the transcription of target gene (36, 113-116). 
 
1.3.2   Dichotomous role of ATF3 in cancer progression 
 ATF3 expression is induced by various cellular stresses such as hypoxia, 
anoxia, carcinogens, cytokines, genotoxic agents, and cell death-inducing compounds, 
which suggested that ATF3 expression may associate with and mediates diverse 
biological consequences. Currently, the debate on the role ATF3 plays in the cancer 
progression is rather conflicting and confusing. The following part will briefly review the 
several biological processes associated with ATF3 expression. 
 
 11 
ATF3 and apoptosis 
 Apoptosis, referred as cell programed death, which is an essential cellular 
process in the normal cell progression and maintain the hemostasis in the body. The 
resistance to apoptosis is significant mechanism of  malignance and poor prognosis in 
many types of human cancers. Quite a few research evidences studied the role of 
ATF3 in apoptosis; nevertheless, a conclusion is still obscure.  
 ATF3 expression remains low in many cancer cell lines (36, 113). However, 
stable or transient overexpression of ATF3 increased caspase protease activation and 
promoted the etoposide or camptothecin induced apoptosis in HeLa cells (117). 
Furthermore, ATF3 expression can be induced by PI3K inhibitor, LY294002, 
followed by the induction of apoptosis in several colorectal cancer cell lines (118). 
ATF3 is molecular target of many anti-cancer compounds such as epicatechin gallate 
(39),  indole-3-carbinol (40), genistein (119), 5’-FU (120), Zerumbone (121), 
Dexrazoxane (122), sulindac sulfide (123), tolfenamic acid (124), HDAC inhibitor 
(125), troglitazone (45), metformin (126). Consistently, in in vivo condition, 
expression of ATF3 is linked with functional defects in several target tissues. 
Transgenic mice expressing ATF3 showed dysfunction in the liver and defects in 
endocrine pancreas development (127, 128). Overexpression of ATF3 in the heart 
displayed atrial enlargement and ventricular hypertrophy (129), which is associated 
with pro-apoptotic functions of ATF3.  
 On the other hand, ATF3 was also reported to play a role in protecting the cells 
from apoptosis. It was reported that overexpression of ATF3 by adenovirus can inhibit 
the apoptosis through activating cell survival signal such as mitogen-activated kinase 
kinase 1 (MEKK1) c-Jun N-terminal kinase (JNK)-dependent pathway and enhanced 
neurite elongation through Akt activation in PC12 cells (130). ATF3 also protected 
human umbilical vein endothelial cells from tumor necrosis factor (TNF)-α-induced 
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apoptosis (122, 131). Recently, Yin reported that ATF3 enhances apoptosis in the 
untransformed MCF10A mammary epithelial cells, whereas protects the aggressive 
MCF10CA1a cells and enhances its cell motility (132). Taken together, the role of ATF3 
in apoptosis depends on the cell type, tissue context.  
 
ATF3 and metastasis 
 The first paper studying a role of ATF3 in metastasis came out in the late of 
twenty century. Ishiguro’s group found that transfection of ATF3 into the low 
metastatic clone F1 can switch the parental cells from low- to high- metastatic cells 
(133). In their follow-up research, ATF3 antisense oligonucleotide changed cell 
morphology and enhanced migration of HT29 colon cancer cells, and improved 
mouse survival in vivo (46). Another research group also found that ATF3 was highly 
expressed at higher levels in the cell lines derived from metastatic sites than in those 
from original tumor sites when they are screening cancer cell lines and surgically 
excised human colon cancer samples (134). Bottone’s group found overexpression of 
full-length ATF3 protein in colorectal cancer cells was associated with decreased 
tumor cell invasion, indicating a anti--tumorigenic role for ATF3 (45). However, 
recently study indicated the involvement of ATF3 in metastasis. A paper published 
recently found that ATF3 knockout mice have less cancer metastasis, indicating that 
ATF3 facilitated metastasis (135). Breast cancer model showed that ATF3 protects 
the high-grade malignant breast cells MCF10CA1a and enhances its cell motility by 
promoting transcription of the TWIST1, FN-1, Snail and Slug genes (132). ATF3 also 
promoted in vitro motility and invasion in both HT29 and CaCO2 cells (136) . 
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Chapter 2. Materials and Methods 
2.1. Cell culture, reagents, and antibodies 
Human colorectal adenocarcinoma cells HCT116, LoVo, CaCo2, SW480, HT-29 
were purchased from American Type Culture Collection (ATCC; Manassas, VA) and 
grown in Dulbecco’s modified Eagle medium (DMEM/F12) supplemented with 10% 
fetal bovine serum (FBS). Normal human colon cells, CCD112CoN was purchased 
from ATCC and grown in Eagle’s Minimal Essential Medium (EMEM) supplemented 
with 10% FBS. The cells were maintained at 37 ºC under a humidified atmosphere of 
5% CO2. Primary and secondary antibodies are obtained from the following source: 
anti-ATF3 (Santa Cruz, anta Cruz, CA), anti-Bcl-2 (BD Biosciences, San Jose, CA), 
anti-Bim, anti-Bcl-xL, anti-Bak, anti-Bad, anti-Bax, anti-Cyclin D1, anti-p21, anti-
p27, anti-Gsk3beta, anti-beta-catenin, anti-p-ERK, anti-p-Akt, anti-Rb, anti-CD44, 
anti-ZO-1, and anti-beta-actin (Cell Signaling, Beverly, MA). 
 
2.2. Generation of colon cancer cells with ATF3 knockdown or ectopic expression of 
ATF3 
Transient transfections were performed using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instruction. The pCG-ATF3 expression construct was 
generously provided by Dr. T Hai (Ohio State University, Columbus, OH, USA). 
pcDNA3.1 his/v5 empty vector was used as control. HCT116 , HCT15, SW480 and 
HT29 cells were plated in 6-well plates at the concentration of 4×10
5
cells/well. The 
next day, plasmid mixtures containing 2.5 µg of ATF3 promoter linked to luciferase 
and 2.5 µg of pcDNA3.1 his/v5 vector were transfected for 48h, respectively.  
Endogenous knockdown of ATF3 was performed using TransIT-TKO transfection 
reagent (Mirus) according to the manufacturer’s instruction. 10 μl of TransIT-TKO 
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reagent was added into 100 μL of Opti-MEMI Reduced-Serum Medium (Solution A). 
Then control (cont) small interfering RNA (siRNA; 100 nM) or ATF3 siRNA 
(siATF3; 100 nM) was mixed with Solution A (Solution B and Solution C). HCT116 
cells were transfected with Solution B and Solution C for 24 hours. 
 
2.3. SDS-PAGE and western blot 
Cells were washed with ice-cold 1 × phosphate-buffered saline (PBS), and cell pellets 
were resuspended in radioimmunoprecipitation assay (RIPA) buffer (Boston Bio 
Products, Ashland, MA, USA) supplemented with protease and phosphatase inhibitor 
cocktail (Sigma Aldrich, St. Louis, MO). The cell suspension was centrifuged at 
12,000 × g for 10 min at 4°C. Protein content was measured by the bicinchoninic acid 
(BCA) protein assay (Pierce, Rockford, IL, USA). Equal amounts of proteins were 
separated on 8%, 10%, 12% or 14% SDS-PAGE, transferred to nitrocellulose 
membranes (Osmonics, Minnetonka, MN, USA) and blocked for non-specific binding 
with 5% non-fat dry milk in Tris-buffered saline containing 0.05% Tween 20 (TBS-T) 
for 1 h at room temperature. Membranes were probed with specific primary 
antibodies in 5% nonfat dry milk at 4 °C overnight and then with horse radish 
peroxidase (HRP)-conjugated immunoglobulin G (IgG) for 1 h at room temperature. 
Chemiluminescence was detected with Pierce ECL Western blotting substrate 
(Thermo Scientific) and visualized by ChemiDoc MP Imaging system (Bio-Rad, 
Hercules, CA, USA).  
 
2.4. Isolation of RNA and semi-quantitative RT-PCR  
Total RNA was prepared using a RNeasy Mini kit (Qiagen). Total RNA (1 μg) was 
reverse-transcribed with the Verso cDNA kit (Thermo Scientific) according to the 
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manufacturer’s instruction. PCR was carried out using ReadyMix Taq polymerase 
(Sigma). 
Primers used in this study 
Gene Forward (5'-3') Reverse (5'-3') 
ATF3 GTTTGAGGATTTTGCTAACCTGAC AGCTGCAATCTTATTTCTTTCTCGT 
GAPDH GGGCTGCTTTTAACTCTGGT TGGCAGGTTTTTCTAGACGG 
E-Cadherin TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC 
N-Cadherin  ACAGTGGCCACCTACAAAGG CCGAGATGGGGTTGATAATG 
Vimentin  GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC 
Snail CCTCCCTGTCAGATGAGGAC CCAGGCTGAGGTATTCCTTG 
Twist GGAGTCCGCAGTCTTACGAG TCTGGAGGACCTGGTAGAGG 
Slug  GGGGAGAAGCCTTTTTCTTG TCCTCATGTTTGTGCAGGAG 
 
2.5. Tumorsphere assay 
Cells were plated at 20,000 cells/mL and grown in 1% methylcellulose on poly–
HEMA coated 6-well plates in DMEM supplemented with 10% serum and 20 ng/ml 
hEGF. Suspension cultures were cultured for 14 days. Then, microscope images were 
taken by phase-contrast microscope and tumorsphere-forming ability was quantified 
by ImageJ. 
 
2.6. Boyden chamber single-cell migration assay 
Cells (1×10
5
) were plated on 8 μm pore size Transwell filters in either DMEM or 
RPMI medium and allowed to migrate for 24 hours. The transmigrated cells were 
detected with Hoechst fluorescent dye and counted. 
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2.7 Detection of apoptotic cells.  
The DNA contents for control and ATF3 overexpressed HCT-116, HCT15, SW480, 
and HT29 cells were determined by fluorescence-activated cell sorting (FACS) as 
previously described. For detection of apoptosis by ATF3 overexpression, HCT-116 
cells were stained with FITClabeled Annexin V and propidium iodide using Annexin 
V-FITC apoptosis detection kit (BD Biosciences PharMingen, San Diego, CA) 
according manufacturer instruction. Briefly, HCT-116 cells were plated at 3×10
5
 per 
well in six-well plates and transfected with pCG-ATF3 by FuGENE 6 (Roche, 
Indianapolis, IN) for 24 hours. Subsequently, the cells were grown for 24 hours and 
stained with Annexin V-FITC and propidium iodide. A total of 10,000 cells were 
examined by flow cytometry using a Beckman Coulter Epixs XL equipped with ADC 
and ModFit LT software. Cells were gated on side scatter and forward scatter to 
exclude debris. Doublets were eliminated using peak versus integral analysis. 
Annexin V–positive/propidium iodide–positive and Annexin V–positive/propidium 
iodide–negative cell populations were determined as apoptotic cells from the total 
gated cells. 
 
2.8. Cell cycle analysis 
Analysis of cell cycle progression was performed by using flow cytometry. The 
confluent 2-day HCT116 cells were harvested. Then, harvested cells were fixed with 
70% ethanol for 2 h at 4 °C, washed with PBS, and centrifuged. The resulting pellet 
was stained with 40 μg per mL propidium iodine solution containing 1 mg per mL 
RNase A at 37 °C for 30 min. The cell cycle progression of samples 10,000 cells was 
analyzed using flow cytometer according to the manufacturer's instructions. 
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 2.9. Statistics 
Statistical analysis was performed with IBM SPSS and the data was analyzed by 
Student t test. Data was expressed as means ± SD and differences were considered 



















Chapter 3: The dual biological function of ATF3 in colon cancer 
progression 
3.1 Low expression of ATF3 in colon cancer cell lines 
Previous evidences indicated that ATF3 is stress-inducible gene, however its basal 
mRNA and protein level is nearly undetectable in most colon cancer cell lines. In 
order to compare basal expression of ATF3 in colorectal cancer cell lines with 
different genetic backgrounds, we examined the mRNA and protein level of 
endogenous ATF3 in multiple colon cancer cell lysates including normal human colon 
CCD-112CoN, human colon adenocarcinoma HCT116, SW480, LoVo, CaCO2, 
HCT15 and HT29. Indeed, we found ATF3 mRNA expression was almost 
undetectable in normal human colon CCD-112CoN, colon cancer cell line HCT116, 
SW480 at mRNA level by RT-PCR (Figure 3.1A).  Protein level of ATF3 was 
detected by western blot. Similarly, low level of indigenous ATF3 was observed in 
HCT116, HCT15, HT29 and SW480 (Similarly 3.1.B), however higher expression of 
ATF3 was observed in LoVo and Caco-2 cells. Based on these results, we choose 











Figure 3.1. ATF3 expression in colon cancer cell lines  
 
 
Figure 3. 1. ATF3 expression in colon cancer cell lines. (A) Colon cancer cell 
lysates were harvested and semiquantitative reverse transcriptase (RT)-PCR was 
performed for ATF3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (B) 
Western blot was performed to analyze the basal expression level of ATF3 and β-







3.2 ATF3 induces apoptosis in colon cancer 
To determine whether gain of function of ATF3 in colon cancer cells can induce the 
apoptosis, we stained HCT116 cells with Annexin V-FITC and propidium iodide and 
analyzed by flow cytometry. We observed significance for the apoptotic cell 
populations after transfection with pCG-ATF3. Result was calculated by Student’s t 
test. 
Figure 3.2. ATF3 induces apoptosis in colon cancer 
 
 
Figure 3.2 Overexpression of ATF3 induces apoptosis in HCT116 cells. HCT-116 
cells were transfected with empty and pCG-ATF3 expression vectors. The cells were 
grown for 24 hours and subsequently stained with Annexin V-FITC and propidium 
iodide and analyzed by flow cytometry. Columns, mean from three independent 
transfections; bars, SD. Apoptotic cell populations after transfection with pCG-ATF3 


























3.3  ATF3 modulates Bcl-2 family members  
Next we tested if ATF3-mediated apoptosis in human colorectal cancer cells is 
associated with Bcl-2 family proteins. Then western blot was performed to detect the 
protein level of Bcl-2 family members. As shown in Fig. 3.3, overexpression of ATF3 
decrease the protein level of Bcl-2, whereas increase the expression level of Bak. No 
change was detected in other Bcl-2 family members.  This result provides evidence of 
potential interaction between ATF3, Bcl-2 and Bak. 
 





Figure 3. 3.  ATF3 modulates the protein and mRNA expression of some Bcl-2 
family genes (a) ATF3 expression vector was transfected into colon cancer cells 
HCT-116 using lipofectamine2000 for 48 hours and then the cells were harvested. 

























3.4 ATF3 inversely regulates Bcl-2 expression.  
To further determine whether ATF3 mediates the expression of Bcl-2, we 
overexpressed ATF3 in three different types of colorectal cancer cells (HCT116, 
HCT15 and SW480) and carried out western blot analysis for ATF3, Bcl-2 and β-
actin. Decreased of Bcl-2 expression was observed after ATF3 expression in HCT116, 
HCT15, but SW480 cells did not express Bcl-2 (figure 3.4A). Meanwhile, we 
knockdown endogenous ATF3 in HCT116 cell line using small interfering RNA 
(siRNA) targeting ATF3 (siRNA). Inversely, Bcl-2 protein was elevated when ATF3 
was suppressed (figure 3.4B). To access whether these changes occurred at a 
transcriptional level, a semi-quantitative RT-PCR was performed. As shown in Figure 
3.4C, overexpressed ATF3 resulted in decrease in the Bcl-2 on mRNA expression 
level. Whereas, Bak was increased in ATF3 overexpressed HCT116 cells (Figure3.4D) 
in mRNA level. 
 









Figure 3.4 Overexpression and knockdown of ATF3 inversely regulate Bcl-2 
protein levels. (A) Control or pCG-ATF3 expression vector was transfected into 
colon cancer cells HCT116, HCT15 and SW480 using lipofectamine2000 for 48 
hours and then the cells were harvested. Western blot analysis was performed for 
ATF3, Bcl-2 and β-actin. (B) HCT-116 cells were transfected with control (cont) 
small interfering RNA (siRNA; 100nM) or ATF3 siRNA (siATF3; 100nM) for 24 
hours using a TransIT-TKO transfection reagent. Western blot analysis was 
performed for ATF3, Bcl-2 and beta-actin.  (C) Control or pCG-ATF3 expression 
vector was transfected into colon cancer cells HCT116, HCT15 and SW480 using 
lipofectamine2000 for 48 hours and then RT-PCR was performed for ATF3, Bcl-2 
and GAPDH.(D) Control or pCG-ATF3 expression vector was transfected into colon 
cancer cells HCT-116 using lipofectamine2000 for 48 hours and then RT-PCR was 







3.5 ATF3 has limited effect on cell cycle regulation.  
According to literature, protective activity of ATF3 in invasive breast cancer cells is 
mediated by activating cell cycle arrest (Yin, 2008).  To determine whether ATF3 
affects cell cycle in colon cancer, we analyzed the fraction of each phase in cell cycle 
after ATF3 expression using FACS analysis and western blot. As shown in Figure 3.5 
A, restoration of ATF3 in HCT116 cells results in a slight decrease in G1 phase, but a 
gain in S and G2-M phase. Inversely, suppression of ATF3 in HCT116 cells resulted 
in minimal G1 arrest, and decreased S and G2-M phase. However, we did not observe 
any changes associated with cell cycle regulatory gene such as cyclin D1 and cyclin-
dependent kinase (CDK) inhibitor p21, p27 (Figure 3.5 C).  These data suggest that 
ATF3 may have minimal effect on the cell cycle regulation.  





























































Figure 3.5. ATF3 has limited effect on cell cycle regulation. (a) HCT116 cells were 
transfected with control vector (OC), ATF3 vector (OA), control knockdown (SC), 
ATF3 knockdown (SA) for 48h and then cultured and analyzed by FACS. Values are 
means ± SD, n=3. Means without a common letter differ, P ≤0.05. (b) ATF3 was 
transfected into colon cancer cells HCT116 and HCT15 using PolyJet for 48 hours 
and then the cells were harvested. Western blot analysis was performed for ATF3, 




3.6 Regulation of EMT-related gene expression by ATF3 in colon cancer cell lines. 
To test whether ectopic expression of ATF3 affects EMT-related gene expression 
profile, we performed RT-PCR to assess Slug, Snail, Vimentin, E-cadherin, N-
cadherin, and Twist in HCT116, HCT15, SW480 and HT29 cells. Slug was decreased 
in HCT116, SW480, and HT29; Snail was reduced in HT29 and Vimentin was 
lessened in SW480. Interestingly, HT15 showed opposite expression of Slug, Snail 
and Vimentin, all of which were elevated after the introduction of ectopic ATF3. 
To further elucidate the mechanism associated with the change of EMT-related gene 
profile, we checked the protein expression level of Gsk3beta, Beta-catenin, p-ERK, 
ERK, and p-Akt. Gsk3beta was enforced associated with the diminished expression of 
beta-catenin in ATF3 overexpressed HCT116 cells. In addition, the expression of p-




















Figure 3.6 Regulation of EMT-related gene expressions by ATF3 in colon cancer 
cell lines. (A) Colon cancer HCT116, HCT15, SW480, HT29 cell lysates were 
harvested and RT-PCR was performed for ATF3, GAPDH and EMT-related genes. 
(B) Western blot was performed to analyze the expression level of Gsk3beat, beta-















































3.7 ATF3 overexpressed cells do not induce single cell migration  
To address whether ATF3 promotes colon cancer cell motility, we analyzed the cells 
by using Boyden chamber. The result indicates that ectopic expression of ATF3 in 
HCT116 and HCT15 cells does not affect colon cancer cell motility when compared 






Figure 3.7. ATF3 overexpressed cells do not induce single cell migration. (a) 
HCT116 and HCT15 cells were analyzed by Boyden chamber assay for single cell 
migration ability with and without the overexpression of ATF3. Fluorescent images 
and quantification of migrated cells numbers were initiated one week after the 
transient transfection with ATF3 expression vector. Numbers of metastases were 











3.8 Formation of cancer initiating cell features and collective cell invasion 
Rb acts as the key suppressor in metastatic progression and upregulation of CD44 can 
decrease the expression of Rb, which is crucial for initiating collective cell migration 
and metastatic growth (138). To test whether ATF3 expression affects collective cell 
migration, we examined expression level of Rb, CD44, and ZO-1 after overexpression 
of ATF3. The western blot assay showed that ectopic expression of ATF3 in HCT116 
cells can elevate the expression of CD44 alternative splicing v and suppress the 
protein level of Rb. (Fig. 3.8 left)  
The mammosphere forming assay was originally developed by Dontu et al. (101) as a 
way to propagate mammary epithelial stem cells (MaSC) in in vitro. Later, 
researchers started to use it as a surrogate reporter of stem cell and cancer stem cell 
activity for tissue samples, tumors and cell lines (92, 139-141). During circulation, 
undifferentiated stem cells survive, but others die by anoikis in blood. The self-
renewal ability of the stem cells permits the formation of mammospheres in serial 
non-adherent passage. This form of culture system proved to be as a feasible approach 
for isolating and propagation of tumorigenic breast cancer cells from primary tumors 
(140) and metastasis (139). Therefore, to test the tumorsphere forming ability of colon 
cancer cells and their morphology under microscope after overexpression of ATF3, 
we perfomed tumorspheres assay under non-adherent conditions. Morphology of the 
colon cancer cell lines HCT116 with and without ectopic expression of ATF3 
included in the study. Compared to the control, ATF3 overexpressing HCT116 cells 
showed more condensed cell density and formed more protruding and budding sites 
(Figure 3.8, right).  
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Figure 3.8. Formation of cancer initiating cell features and collective cell 
invasion 
 
Figure 3.8. Formation of cancer initiating cell features and collective cell 
invasion (A) HCT-116 cells were transfected with ATF3 expression vector using 
PolyJet for 48 hours and western blot was performed for ATF3, Rb, CD44, ZO-1 and 
beta-actin. (B) Phase contrast images and quantification of tumorsphere-forming were 









Chapter 4. Discussion, Conclusions, and Future Perspective  
4.1 Discussion 
 ATF3 gene expression can be induced by a variety of stress signals, including 
those encountered by cancer cells during their development (carcinogens, DNA 
damage, hypoxia, anoxia etc.) (36, 38), as well as signals commonly present in the 
tumor microenvironment (142, 143). Therefore, ATF3 is considered as an adaptive-
response gene that participates in cellular processes to adapt to extra- and/or intra 
cellar changes and functions as a hub in the biological network that allows cell to 
respond to signals disrupting homeostasis (144). 
 The cyclic AMP response element (CRE) is a major positive regulatory site in 
the bcl-2 promoter, which plays an important functional role in the regulation of 
endogenous Bcl-2 expression and apoptosis (145). Previous researches revealed that 
CRE binding protein ATF/CREB can form selective heterodimers with each other or 
other bZip proteins such as the AP-1 and C/EBP families of proteins. The formation 
of the heterodimer can alter DNA binding specificity and transcriptional activities 
(43). Therefore, ATF3 may regulate Bcl-2 by binding to the promoter region of Bcl-2 
in colon cancer cell lines including HCT116, HT29, and SW480. Whether Bak, the 
pro-apoptosis protein from Bcl-2 family, is activated directly by ATF3, or indirectly 
as a consequence of neutralization of pro-survival targets Bcl-2 is the subject 
deserved further discussion. A detailed understanding of the interactions between 
ATF3 and Bcl-2 family members provided by the current research has notable 
implications for designing anti-cancer drugs to target the Bcl-2 family, thus triggering 
apoptosis in cancer cells (146).  
 Interestingly, expression of ATF3 protein is shown to have limited effect on 
cell cycle regulation. In agreement with this observation, we have also noticed that 
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cell cycle progression of protein markers, such as cyclins and cyclin-dependent 
kinases (CDKs), and their inhibitors p21 and p27, were not changed after induction of 
ATF3 in HCT116 and HCT15 cells. However, previous research found that 
overexpression of ATF3 using the tetracycline-inducible system can moderately slow 
down progression of cells from G1 to S phase, indicating that ATF3 protein might be 
a candidate in the control of cell cycle progression (147). This might be due to the 
variation of tissue and cellular environment and use of different means of inducing 
ATF3. The future investigation is required to understand whether ATF3 protein 
function differently when cellular or tissue environment changed.  
 In our study, ATF3 potentially suppresses EMT by regulating of EMT-related 
gene expression in HCT116, HT29 and SW480 cell lines. Here, we propose three 
mechanisms. Firstly, we observed that the overexpression of ATF3 leads to 
stimulation of Wnt pathway, which induces the expression of GSK-3β, consequently, 
lower the expression level of β-catenin (Figure 3.6B). The glycogen synthase kinase-
3β (GSK3β) promotes stabilization of cytoplasmic β-catenin, which inhibits the 
translocation of β-catenin to the nucleus and stops its binding to the transcription 
factors lymphoid enhancer-binding factor 1 (LEF) and T cell factor (TCF). This 
action inhibits gene expression program that suppress EMT (68). Secondly, in the 
present study, we also observed that SNAIL family transcription factors, Slug and 
Snail, are decreased after induction of ATF3. Snail family transcription factors are 
well known to stimulate EMT. Previous studies have shown that Snail or Slug can 
repress the E-cadherin by binding to E-box DNA sequences in the promoter region 
(68). Additionally, SNAIL can also induce the mesenchymal phenotype by activating 
N-cadherin. Downregulation of E-cadherin and induction of N-cadherin can result in 
the alteration of cell adhesion, which is essential of the initiation of EMT. Thirdly, 
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EMT responses can also be induced by crosstalk and cooperation between distinct 
pathways. Our result showed that the increase of exogenous ATF3 in colon cancer 
cell line can activate the phosphorylation of Akt and Eer proteins, which ameliorates 
the EMT signaling. The integrin-induced Akt activation can cooperating with Wnt 
signaling by inhibiting GSK3β, thus inducing SNAIL expression through nuclear 
factor-κB (NF-κB) and stabilizing SNAIL and β-catenin (68).    
 In addition to promoting EMT through Wnt pathway, transforming growth 
factor-β (TGFβ) can activate the PI3K–Akt, Erk MAPK, p38 MAPK and Jun N-
terminal kinase (JNK) pathways. TGF-β3 signaling induces formation of beta-
catenin–LEF-1 complexes that initiate EMT by up-regulating the synthesis of Snail 
and Slug (72).   
 Interestingly, HCT15 cell lines showed different expression profile of EMT-
related genes. Unlikely HCT116, SW480 and HT29 cells, HCT15 cells have elevated 
Slug, Snail and vimentin mRNA expression level after ATF3 expression. One of the 
possible reasons is that HCT15 carry disrupted MSH6. He et al., proposed a 
correlation between low content of MSH6 and elevated EMT (152). Low level of 
MSH6 (153, 154) activates alternative lengthening of telomeres (ALT) and promote 
cancer progression at advanced stages through promoting EMT (152). However, 
whether the low level of MSH6 can trigger the display of EMT characteristic remains 
unknown. Further investigation is required to address this issue.  
 Another interesting finding in current study is that ATF3 suppresses Rb and 
stimulates the expression of CD44, a marker of colon cancer stem cell. The 
development of metastasis consists of underlying rate-limiting multistage steps (148). 
However, metastatic colonization, the successful initiation of metastatic growth, is not 
frequently seen and inefficient for many cancer types except a minority of cancer cells 
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that reach distant sites (149, 150). A subpopulation of cancer stem cells is pivotal for 
metastatic colonization, and the interaction with stromal niche signals are crucial to 
the expansion process (151).  
 Previous research indicates that ATF3 enhance cancer-initiating cell features 
by increasing the population of CD44
high
 cells, the mammosphere-forming ability, and 
the tumor-initiating frequency in breast cancer (144). We observed that ectopic 
expression of ATF3 in colon cancer cells processes the ability to increase cancer-
initiating cell features and holds the metastasis potential, which paves the way for 
various stromal signals to exert their impact by inducing ATF3, a hub of the 

















4.2 Conclusion and Future Perspectives 
 The present study suggests potential dual function of ATF3 in the 
development of human colorectal cancer. Data presented in Chapter 3 revealed that 
ATF3 can modulate the protein and mRNA expression of some Bcl-2 family genes, 
and enhance apoptosis in different colorectal cancer cells. Though, minimal effect of 
ATF3 generated on cell cycle regulation. This result indicated a tumor suppressive 
role of ATF3. Without triggering the single cell migration, however, induction of 
ATF3 exerts differential regulation effect of EMT-related gene markers in different 
colon cancer cells. Overexpression of ATF3 can enhance the tumorsphere forming 
ability and promote primary tumor growth, consequently, contribute to the collective 
tumor invasion. This finding provides correlative evidence to support an oncogenic 
role of ATF3.    
 However, much more work remains to further investigate the mechanisms and 
functions of ATF3 in human colon cancer. First, in our study, we use overexpression 
of ectopic ATF3 in colon cancer, but the effects and function of signal-induced or 
compound-induced expression of ATF3 may be different. Secondly, using the gene 
overexpression and knockdown strategy, we demonstrated that ATF3 directly regulate 
the gene expression of Bcl-2. While we do not know whether Bcl-2 can inversely 
regulate ATF3. Double overexpression or double knockdown strategy is needed to 
elucidate the relationship between Bcl-2 and ATF3. Thirdly, to further examine the 
collective cell invasion activity after gain function of ATF3 in colon cancer cells, we 
can test cell surface proteases, including MT1MMP and MMP2, which are acclaimed 
to be engaged in degrading the ECM substrate and participate in the ECM remodeling, 
an early event in collective cancer cell movement (158, 159). Fourthly, given the 
importance of ATF3 in cellular context, it is also crucial to investigate how ATF3 
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function in vivo situation. Physiological mechanisms that regulate biological events 
are very complex and the biological system for investigating disease process 
sometimes can be different from in vitro study. To test whether ATF3 can induce the 
metastasis in colorectal cancer in vivo, we can use tail vein injection lung metastasis 
animal model.  
 Previous studies have revealed that ATF3 can be induced by a variety of anti-
tumorigenic compounds including indole-3-carbinol (40), conjugated linoleic acid 
(41), tolfenamic acid (124), epicatechin gallate (39), resveratrol (42), paclitaxel (160) 
and PI3 kinase inhibitor (118). Some of these compounds have entered into clinical 
trails. However, the possible oncogenic property of ATF3 can bring the side effect to 
drugs made by these compounds. Thus, it is essential to understand the molecular 
context which determines the function of ATF3 as a tumor suppressor or an oncogene, 
providing the rationale for designing anti-cancer treatment and benefiting the clinical 
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